HAIC + Tislelizumab +lenvatinib

COMBINATION_PRODUCT2 trials

Sponsors

Chen Xiaoping, First Hospital of China Medical University

Conditions

HCCHepatocellular Carcinoma (HCC)Portal Vein Tumor ThrombusPrecision Therapy

Phase 1

Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models

RecruitingNCT06463444

Chen XiaopingHCC, Precision Therapy

Start: 2024-06-01End: 2026-06-30Target: 30Updated: 2024-06-17

Phase 2

Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus

RecruitingNCT07483359

First Hospital of China Medical UniversityHepatocellular Carcinoma (HCC), Portal Vein Tumor Thrombus

Start: 2026-05-20End: 2028-05-01Target: 38Updated: 2026-05-28